Lawyers from our Houston and Dallas offices recently advised Baylor College of Medicine on its sale of Diversigen, a biotech pioneer in the growing healthcare field of the human microbiome, to OraSure Technologies Inc.
Orasure is a leader in point of care diagnostic tests and specimen collection and stabilization devices. Diversigen develops solutions for sequencing, analysis, and consulting services geared toward the study of the microbiome of living organisms and environments. A microbiome is the collective organisms of the microbes (comprised of bacteria, bacteriophage, fungi, protozoa and viruses) that live in and on the human body.
Diversigen has a proven track record of taking part in microbiome-focused clinical trials for big pharma clients and cutting-edge microbiome-focused biotech companies.
The team advising Baylor College of Medicine was led by Will Davis (Houston) and included Kaitlin Lolie, Addison Churay, Juan Velasquez, Daniel Prati (Houston) and Todd Schroeder (Dallas).